Meridian Bioscience is a pharmaceuticals business based in the US. Meridian Bioscience shares (VIVO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. Meridian Bioscience employs 690 staff and has a trailing 12-month revenue of around $333 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $33.00 |
| 200-day moving average | $31.18 |
| Wall St. target price | $34.00 |
| PE ratio | 35.3854 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.96 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2023-02-14
| 1 week (2024-10-07) | N/A |
|---|---|
| 1 month (2024-09-14) | N/A |
| 3 months (2024-07-14) | N/A |
| 6 months (2024-04-14) | N/A |
| 1 year (2023-10-14) | N/A |
|---|---|
| 2 years (2022-10-18) | -100.00% |
| 3 years (2021-10-18) | 17.86 |
| 5 years (2019-10-18) | 10.03 |
Valuing Meridian Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Meridian Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Meridian Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Meridian Bioscience shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Meridian Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.33. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Meridian Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Meridian Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $92.1 million.
The EBITDA is a measure of a Meridian Bioscience's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $333 million |
|---|---|
| Operating margin TTM | 22.7% |
| Gross profit TTM | $188.4 million |
| Return on assets TTM | 10.35% |
| Return on equity TTM | 12.19% |
| Profit margin | 12.75% |
| Book value | $8.41 |
| Market Capitalization | $1.5 billion |
TTM: trailing 12 months
We're not expecting Meridian Bioscience to pay a dividend over the next 12 months.
Meridian Bioscience's shares were split on a 3:2 basis on 13 May 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Meridian Bioscience shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Meridian Bioscience shares which in turn could have impacted Meridian Bioscience's share price.
Over the last 12 months, Meridian Bioscience's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Meridian Bioscience's is 0.2319. This would suggest that Meridian Bioscience's shares are less volatile than average (for this exchange).
Meridian Bioscience, Inc. , a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests for Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.